Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
Over the past 5 years, 1846 HIV-infected patients underwent drug resistance testing at our institution. None out of 216 drug-naive subjects showed K65R. However, it was recognized in 53 out of 1630 antiretroviral-experienced patients (3.3%), of whom 10 had never been exposed to tenofovir. The rate of K65R increased from 0.6% in 1999 to 11.5% in 2004. The recognition of K65R correlated negatively with the presence of thymidine analogue mutations but positively with Q151M.
Valer
Luisa
L
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Martín-Carbonero
Luz
L
de Mendoza
Carmen
C
Corral
Angélica
A
Soriano
Vincent
V
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation / Q000235:genetics*; D063065:Organophosphonates / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000068698:Tenofovir; D013936:Thymidine / Q000031:analogs & derivatives / Q000235:genetics*
D019380:Anti-HIV Agents; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D054303:HIV Reverse Transcriptase; D000225:Adenine; D013936:Thymidine